{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigs2zjgujqu2zjc6poq6p35dluvqbfiih3cem6c2yxmkcl4mbeisq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm7qrdnfpjw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifypap64uv6mzt357j67jw2oadaub7762urbwey6fp7edloqlwm3u"
    },
    "mimeType": "image/jpeg",
    "size": 490529
  },
  "path": "/news/2026-05-patients-benefit-tirzepatide-glp-obesity.html",
  "publishedAt": "2026-05-19T10:30:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International Conference narrows down which patients are likely to have the best treatment outcomes.",
  "title": "Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?"
}